ARTICLE SUMMARY:
As medtech innovation expands to include more IT and software elements, so too will the industry’s investor base, increasingly attracting tech VCs who view the world quite differently, as Avail Medsystems found out first-hand.
For all of the science and analytics associated with the go or no-go decision to invest in a start-up company, most venture capitalists will acknowledge that equally important is a certain kind of gut level reaction or “Aha!” moment that flips the switch one way or another. For Peter Hebert, one of the founders of Lux Capital, it was just that kind of experience that convinced him to lead Avail Medsystem Inc.’s Series A and A1 rounds and also to invest in the company’s Series B financing.
